Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 3

Original Research

Physicians’ and pharmacists’ acceptance of online, real-time “drug combinations to avoid” messages

Dong-Sook Kim, Ha-Lim Jeon, Sukhyang Lee, and Nam Kyung Je

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 53 p. 712 - 727

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 53 – No. 9/2015 (712-721)

Physicians’ and pharmacists’ acceptance of online, real-time “drug combinations to avoid” messages

Dong-Sook Kim¹, Ha-Lim Jeon¹, Sukhyang Lee², and Nam Kyung Je³

¹Research Team, Health Insurance Review & Assessment Service, Seoul, ²College of Pharmacy, Ajou University, Suwon, and ³College of Pharmacy, Pusan National University, Busan, Korea
Background: Computerized physician order entry (CPOE) systems combined with a clinical decision-support system (CDSS) can prevent potential drug-therapy problems; however, medication-related decision- support alerts with low specificity often generate alert fatigues and are ignored by health-care providers. The computerized prospective drug utilization review (DUR) program supported by the Korean government has been providing “drug combinations to avoid (DCA)” alerts to physicians and pharmacists since December 2010. Objectives: The aim of this study is to explore providers’ responses to DCA alerts and identify the characteristics of institutions, providers, and drug components associated with providers’ acceptance of online, real-time DCA messages. Methods: A retrospective analysis was conducted on the DUR prescription-transfer data from April 1, 2011 to March 31, 2012 in South Korea. The frequency of DCA alerts and provider acceptance was observed in two ways: “within-prescription review” and “between-prescriptions review”. Multivariate regression was used to determine the predictors of acceptance. Results: The overall acceptance rate was 37.9%, which was relatively high compared with the results from the previous studies with regular drug-drug interaction (DDI) alerts. The acceptance rates varied depending on the origin and types of DCA. The types and location of institutions and severity of DCA were positive predictors of alert acceptance. Conclusions: To improve providers’ adaptation to DCA alerts, various strategies, including tiering, applying human factors, and eliminating inappropriate alerts should be considered.Correspondence to:
Nam Kyung Je, PharmD
Pusan National University
College of Pharmacy, Research Bldg
#532, Busandaehakro 63 Bungil 2,
Geumjeong-Gu, Busan 609-735, Korea
Email: [email protected]

Original Research

Association between use of antiemetics, antipsychotics, or antidepressants and the risk of Parkinson’s disease 

Ju-Young Shin, Ha-Lim Jeon, Han Eol Jeong, Hyeo-Il Ma, and Sunmee Jang

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 57 (2019) p. 73 - 81

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 57 – No. 2/2019 (73-81)

Association between use of antiemetics, antipsychotics, or antidepressants and the risk of Parkinson’s disease 

Ju-Young Shin¹, Ha-Lim Jeon¹, Han Eol Jeong¹, Hyeo-Il Ma², and Sunmee Jang³

¹School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, ²Department of Neurology, College of Medicine, Hallym University, Anyang, Gyeonggi-do, and ³College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, South Korea
Objective: Antipsychotics, antidepressants, and antiemetics are well-known causative agents of parkinsonism. However, it is not certain that the use of these medications increases the risk of Parkinson’s disease (PD). We aim to define the risk of PD associated with use of antipsychotic, antidepressant, or antiemetic therapy. Materials and methods: We conducted a population-based nested case-control study using data from the South Korean health insurance database. For each PD case, we randomly selected sex, age group, cohort entry date, duration of follow-up, and Charlson comorbidity score-matched controls (up to 3). Exposure was categorized into six groups based on treatments received 1 – 90 days before the index date (separate use of either: antiemetics; antipsychotics; or antidepressants; combined use of antiemetics with either: antipsychotics; or antidepressants; and combined use of all three). We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for PD. Results: Final subjects included 31,428 cases and 94,284 matched controls. We observed an increased risk of PD with the separate use of antiemetics (adjusted OR, 1.08; 95% CI, 1.05 – 1.11) and that of antipsychotics (1.31; 1.12 – 1.52), and the combined use of antiemetics and antipsychotics (1.42; 1.15 – 1.75). Both antidepressants alone and with antipsychotics were not associated with higher risk of PD. Conclusions: Separate or concurrent use of antiemetics and antipsychotics showed increased risks of PD. Although statistical significance was observed, when taking into account that there still lie unmeasured, unconsidered confounders, there may be no clinical association present. Caution will be needed in prescribing these drugs in patients who have prognostic factors for PD.  Correspondence to:
Sunmee Jang, PhD
College of Pharmacy and Gachon Institute  of Pharmaceutical Sciences
Gachon University
191 Hambakmoero, Yeonsu-gu, Incheon, 13120, South Korea
Email: [email protected]

Original

Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade:  A two-country comparison 

So-Hee Park, Ha-Lim Jeon, Seoyoung C. Kim, Jodie Hillen, Svetla Gadzhanova, Ju-Young Shin, and Nicole Pratt

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 59 (2021) p. 639 - 644

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 59 – No. 10/2021 (639-644)

Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade:  A two-country comparison 

So-Hee Park¹, Ha-Lim Jeon¹, Seoyoung C. Kim²#³, Jodie Hillen⁵, Svetla Gadzhanova⁵, Ju-Young Shin¹#⁴, and Nicole Pratt⁵

¹School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, ⁴Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea, and ⁵Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia
Objective: To compare trends in the use of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA), between Korea and Australia.
Materials and methods: Using sampled claims databases in Korea and Australia (2010 – 2018), we analyzed the trends in the use of individual targeted DMARDs (biologic and targeted synthetic) for RA in both countries.
Results: The use of targeted DMARDs for the management of RA showed an increase of over 200 and 300% in Australia and Korea, respectively. The tumor necrosis factor inhibitors (TNFis) etanercept and adalimumab were the most commonly prescribed drugs in 2010 in both countries, with non-TNFi use increasing over the study period. The introduction of tofacitinib in 2015 led to 10 and 15% market share uptake in Korea and Australia, respectively.
Conclusion: Trends in the use of targeted DMARDs for RA were similar in Korea and Australia, and the use of non-TNFis, including tofacitinib, increased in both countries.Correspondence to:
 Ju-Young Shin, PhD, Associate Professor
 School of Pharmacy, Sungkyunkwan University
2066 Seobu-ro, Jangan-gu, Suwon,
Gyeonggi-do 16419, Republic of Korea  
or
 Nicole Pratt, PhD, Associate Professor 
Quality Use of Medicines and Pharmacy Research Centre
School of Pharmacy and Medical Sciences
University of South Australia
Adelaide, South Australia, Australia
Email: [email protected]

Shopping Overview

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail